Abstract:Introduction: In mitochondrial DNA (mtDNA) depletion syndrome (MDS), patients cannot maintain sufficient mtDNA for their energy needs. MDS presentations range from infantile encephalopathy with hepatopathy (Alpers syndrome) to adult chronic progressive external ophthalmoplegia. Most are caused by nucleotide imbalance or by defects in the mtDNA replisome. There is currently no curative treatment available. Nucleoside therapy is a promising experimental treatment for TK2 deficiency, where patients are supplemented with exogenous deoxypyrimidines. We aimed to explore the benefits of nucleoside supplementation in POLG and TWNK deficient fibroblasts. Methods: We used high-content fluorescence microscopy with software-based image analysis to assay mtDNA content and membrane potential quantitatively, using vital dyes PicoGreen and MitoTracker Red CMXRos respectively. We tested the effect of 15 combinations (A, T, G, C, AT, AC, AG, CT, CG, GT, ATC, ATG, AGC, TGC, ATGC) of deoxynucleoside supplements on mtDNA content of fibroblasts derived from four patients with MDS (POLG1, POLG2, DGUOK, TWNK) in both a replicating (10% dialysed FCS) and quiescent (0.1% dialysed FCS) state. We used qPCR to measure mtDNA content of supplemented and non-supplemented fibroblasts following mtDNA depletion using 20 μM ddC and after 14- and 21-day recovery in a quiescent state. Results: Nucleoside treatments at 200 μM that significantly increased mtDNA content also significantly reduced the number of cells remaining in culture after 7 days of treatment, as well as mitochondrial membrane potential. These toxic effects were abolished by reducing the concentration of nucleosides to 50 μM. In POLG1 and TWNK cells the combination of ATGC treatment increased mtDNA content the most after 7 days in non-replicating cells. ATGC nucleoside combination significantly increased the rate of mtDNA recovery in quiescent POLG1 cells following mtDNA depletion by ddC. Conclusion: High-content imaging enabled us to link mtDNA copy number with key read-outs linked to patient wellbeing. Elevated G increased mtDNA copy number but severely impaired fibroblast growth, potentially by inhibiting purine synthesis and/or causing replication stress. Combinations of nucleosides ATGC, T, or TC, benefited growth of cells harbouring POLG mutations. These combinations, one of which reflects a commercially available preparation, could be explored further for treatment of POLG patients.

Decoding the mitochondria without a code: mechanistic insights into mitochondrial DNA depletion syndromes

Therapeutic and tampering approaches for mitochondrial associated diseases

Mitochondrial DNA depletion syndrome: new descriptions and the use of citrate synthase as a helpful tool to better characterise the patients

A Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects

Quantitative evaluation of the mitochondrial DNA depletion syndrome

Mitochondrial DNA competition: starving out the mutant genome

Enhanced mitochondrial genome analysis: bioinformatic and long-read sequencing advances and their diagnostic implications

Nucleoside supplements as treatments for mitochondrial DNA depletion syndrome

Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion

Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases

Mitochondrial DNA homeostasis impairment and dopaminergic dysfunction: A trembling balance

A peep into mitochondrial disorder: multifaceted from mitochondrial DNA mutations to nuclear gene modulation

A Clinical-Pathophysiological Perspective

Genetically and Metabolically Corrected Pluripotent Stem Cells from Patients with Mtdna Disease

Advancing Variant Phenotyping in Myelodysplastic Syndromes via Computational Genomics of Mitochondrial Enzyme Complexes

Personalized Medicine in Mitochondrial Health and Disease: Molecular Basis of Therapeutic Approaches Based on Nutritional Supplements and Their Analogs

Genetic basis of mitochondrial diseases

Mitochondrial molecular genetics and human disease

Mitochondrial dysfunction: mechanisms and advances in therapy

Mitochondrial diseases and mtDNA editing

Mitophagy modulation rescues single large-scale mitochondrial DNA deletion (SLSMD) disease symptoms in the C. elegans uaDf5 animal model.